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To the Editor, 
Response to Christopher J.D. Wallis, Zachary Klaassen's Letter to the Editor re: Rydzewska LHM, Burdett S, Vale CL, Clarke NW, 
Fizazi K, Kheoh T et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate 
cancer: a systematic review and meta-analysis. Eur J Cancer. 2017; 84:88-101. https://doi.org/10.1016/j.ejca.2017.07.003 
Our systematic review and meta-analysis was conducted using FAME (Framework for Adaptive Meta-analysis, [1]). This is a 
prospective approach that takes all eligible trials into account and is responsive to emerging trial results. Thus, we would like to 
make clear that the review was initiated well in advance of the two trial results being known, and we anticipated that a meta-
analysis of these trials would provide both a timely and sufficiently reliable result. It would have been near impossible to predict or 
expect that the individual trials would produce such ‘overwhelmingly positive’ or ‘remarkably consistent’ results. 
As Wallis et al. point out, the meta-analysis has improved the precision of the estimate of effect on survival. However, by using 
FAME, working closely with the trial teams, and requesting additional analyses and results, we have been able to do much more ‘to 
advance our understanding of the role of abiraterone in men with metastatic hormone-sensitive prostate cancer’: 
 By obtaining additional unreported progression-free survival (PFS) analyses for STAMPEDE metastatic (M1) patients, we 
have been able to look at the consistency of effect across the two trials and to provide the best estimate of the size of the 
PFS effect. 
 
 By obtaining subgroup analyses just for STAMPEDE M1 patients, and additional analyses of LATITUDE, we have been 
able to investigate whether the effects of abiraterone on survival and PFS are consistent across different types of men, 
with greater power than the individual trials and using analyses that are not usually possible with aggregate data [2]. 
 
 In particular, we showed that the difference in effect by age group seen in STAMPEDE remains in the pooled analysis and 
requires further investigation with individual participant data (IPD). 
 
 By collecting consistently defined G3-4 and G5 acute toxicity for both trials, and just for STAMPEDE M1 patients, we have 
provided the first formal analysis of these outcomes, both within and across trials. We found an increase in serious acute 
cardiac, vascular and hepatic side-effects with abiraterone, but no excess of deaths. 
 
 By obtaining up-to date information on the PEACE-1 trial, we were able to place the results in the context of all the 
potential evidence. 
 
We very much agree that there is now a need to compare the relative efficacy of different treatments, including docetaxel and 
abiraterone, and this review feeds into a network meta-analysis based on aggregate data [3]. Our results suggest that adding 
abiraterone to androgen deprivation therapy (ADT) is likely to be the most effective, and docetaxel plus ADT the second most 
effective treatment in improving survival in men with metastatic hormone-sensitive prostate cancer, although some uncertainty 
remains about the absolute difference in survival benefit between these two treatments and how trial and patient variability impacts 
on these results. Our ongoing collection of IPD will help us determine more definitively which therapies work best, and for which 
men. 
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